(PharmaNewsWire.Com, October 19, 2020 ) Bowel/fecal incontinence refers to a patient’s inability to control bowel movements, which results in involuntary loss of solid or liquid stool. It is caused due to diarrhea, constipation, weaker muscle tone (that controls the opening of the anus), and chronic medical conditions (such as diabetes, multiple sclerosis, and nerve damage). The clinical devices used to manage bowel activity are called bowel management systems
The global bowel management systems market is projected to reach USD 2.07 billion by 2023 from USD 1.74 billion in 2018, at a CAGR of 3.5% during the forecast period.
Some of the major factors driving the growth of this market are: expanding target patient population, rapidly growing geriatric population, availability of technologically advanced bowel management products, and favorable reimbursement scenario in developed countries.
Global Industry Segmentation:
The colostomy bags segment is expected to form the largest segment during the forecast period.
Based on product, the bowel management systems market is categorized into four major segments, namely, irrigation systems, nerve modulation devices, colostomy bags, and other products & accessories. The colostomy bags segment is expected to account for the largest share in the bowel management systems market in 2018. Increasing number of target patient population, and growing availability of medical reimbursements for colostomy products across developed markets are expected to drive the growth of the colostomy bags segment in the next five years.
In 2018, Europe accounted for the largest share of the bowel management systems market
Geographically, the bowel management systems market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Europe accounted for the largest share of the market in 2018. The large share can be attributed to the significant disease (colorectal/bladder cancer & IBD) burden, favorable reimbursement scenario, and the increase in its geriatric population.
The home care segment is estimated to register the highest growth rate in the bowel management systems market during the forecast period
The bowel management systems market is segmented, by end user, into home care and hospitals & ambulatory surgery centers. The home care segment is expected to register the highest growth rate of the bowel management systems market during the forecast period, owing to the factors such as the significant usage and growing adoption of bowel management products in home care settings, and need for device replacement on a regular basis.
Adult patients segment is estimated to register the highest growth rate in the bowel management systems market during the forecast period
The bowel management systems market is segmented, by patient type, into adult and pediatric patients. The adult patients segment is expected to register the highest growth rate in the bowel management systems market during the forecast period, owing to the factors such as the significant prevalence of FI among adults, increased public-private initiatives to enhance patient awareness related to effective FI management, and availability of advanced bowel management products.
Global Leaders:
Some of the major players operating in the bowel management systems market are Coloplast (Denmark), Medtronic (Ireland), 3M (US), B. Braun (Germany), C.R. Bard (US), Consure Medical (India), Cogentix Medical (US), Aquaflush Medical Limited (UK), Axonics Modulation Technologies (US), ConvaTec (UK), Hollister (US), MBH-International A/S (Denmark), Mederi Therapeutics Inc. (US), Welland Medical limited (UK), and Wellspect HealthCare (Sweden).
An analysis of market developments between 2015 and 2018 revealed that growth strategies such as product launches and approvals, agreements, expansions, and acquisitions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the bowel management systems market. Among these, product launches and approvals were the most widely adopted growth strategies
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
